In fact, researchers have found that proteomic analysis identified typical tumor markers, including FSTL5, ART3, and FMOD, and revealed the prevalence of anti-inflammatory and tumor-promoting proteins that are characteristic of myeloid cells in CSF from patients with MB (26). This evidence concerns the gene FSTL5 and neoplasm.